Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
33.60B
Market cap33.60B
Price-Earnings ratio
-106.34
Price-Earnings ratio-106.34
Dividend yield
Dividend yield
Average volume
1.31M
Average volume1.31M
High today
High today
Low today
Low today
Open price
$243.12
Open price$243.12
Volume
0.00
Volume0.00
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

The current Natera(NTRA) stock price is $242.91, with a market capitalization of 33.6B. The stock trades at a price-to-earnings (P/E) ratio of -106.34.

On 2026-01-23, Natera(NTRA) stock opened at $243.12, reached a high of —, and a low of —.

Natera(NTRA) shares are trading with a volume of 0, against a daily average of 1.31M.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

NTRA News

TipRanks 2d
Natera announces publication of validation study for Latitude tissue-free assay

Natera (NTRA) announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay, or tfMR...

Simply Wall St 5d
Assessing Natera Valuation After AI Oncology Advances And Strong 2025 Growth Guidance

Natera (NTRA) is back in focus after issuing guidance that points to a 39% year over year jump in Q4 revenue, projected 35% full year 2025 revenue growth, and f...

Assessing Natera Valuation After AI Oncology Advances And Strong 2025 Growth Guidance
Nasdaq 7d
First Week of NTRA March 20th Options Trading

Investors in Natera Inc (Symbol: NTRA) saw new options begin trading this week, for the March 20th expiration. At Stock Options Channel , our YieldBoost formula...

First Week of NTRA March 20th Options Trading

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.